Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
  • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
  • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
  • A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/06—Antipsoriatics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/12—Antihypertensives

Definitions

• the present inventions relate to pharmaceutical formulations of prostacyclin analogs and their storage methods and, in particular, to solid formulations of prostacyclin analogs and their storage methods.
• a pharmaceutical product comprises a pharmaceutical packaging configured to maintain a moisture level of greater than 3% and no more than 7%; and a solid formulation inside the packaging, wherein the formulation comprises a active agent having formula I:
• a pharmaceutical product comprises (a) a pharmaceutical packaging; (b) a solid formulation inside the packaging, wherein the formulation comprises a active agent having formula I:
• R 1 is independently selected from the group consisting of H, substituted and unsubstituted benzyl groups, and groups wherein OR are substituted or unsubstituted glycolamide esters;
• R and R may be the same or different and are independently selected from the group consisting of H, phosphate and groups wherein OR 2 and OR 3 form esters of amino acids or proteins, or an enantiomer or a pharmaceutically acceptable salt thereof;
• a desiccant inside the packaging wherein an amount of the desiccant in the packaging is less than an effective amount for maintaining a relative humidity level inside the packaging for a storage time of the formulation below 40%.
• a storage method comprising: storing a solid formulation inside a pharmaceutical packaging, wherein the formulation comprises an active agent having formula I:
• R 1 is independently selected from the group consisting of H, substituted and unsubstituted benzyl groups, and groups wherein OR are substituted or unsubstituted glycolamide esters;
• R 2 and R 3 may be the same or different and are independently selected from the group consisting of H, phosphate and groups wherein OR 2 and OR 3 form esters of amino acids or proteins, or an enantiomer or a pharmaceutically acceptable salt thereof; wherein a moisture level in the solid formulation after said storing is greater than 3% and no more than 7%.
• a storage method comprises storing a solid formulation and a desiccant inside a pharmaceutical packaging, wherein the formulation comprises an active agent having formula I:
• R 1 is independently selected from the group consisting of H, substituted and unsubstituted benzyl groups, and groups wherein OR are substituted or unsubstituted glycolamide esters
• R 2 and R 3 may be the same or different and are independently selected from the group consisting of H, phosphate and groups wherein OR 2 and OR 3 form esters of amino acids or proteins, or an enantiomer or a pharmaceutically acceptable salt thereof; wherein an amount of the desiccant is less that an effective amount for maintaining a relative humidity level inside the packaging during said storing below 40%.
• solid formulations containing one or more pharmaceutical compounds are typically packaged with an effective amount of a drying agent or desiccant so that the drying agent or desiccant maintains the humidity level inside the packaging at a low level, which may be, for example, below 40 % relative humidity for a storage temperature during the whole storage time.
• a moderate moisture level may be beneficial for solid formulations of certain prostacyclin analogs.
• the moderate moisture level in such formulations may result in less degradation and/or less unfavorable impurities compared to a formulation with a minimal moisture content, which may be a moisture level below 3%.
• a pharmaceutical product may comprise a pharmaceutical packaging configured to maintain a moderate moisture level inside the packaging and a solid formulation comprising, as an active agent, a prostacyclin analog.
• a pharmaceutical packaging configured to maintain a moderate moisture level inside the packaging and a solid formulation comprising, as an active agent, a prostacyclin analog.
• prostacyclin analogs which may be used as an active agent are disclosed in the section "Active agent".
• the moderate moisture level may be a level that is greater than 3 % and less than a moisture level effective to dissolve a component of the formulation.
• the moderate moisture level may be greater than 3 % and no greater than 7 % ; or greater than 3 % and no greater than 6 %; or greater than 3 % and no greater than 5.5 %; or greater than 3 % and no greater than 5 %; or greater than 3 % and no greater than 4.5 %; no less than 3.5 % and no greater than 7 %; or no less than 3.5 % and no greater than 6 %; or no less than 3.5 % and no greater than 5 %; or no less than 3.5 % and no greater than 4.5 %.
• Procedures for measuring moisture levels in solid form formulations are known to those of ordinary skill in the art.
• the present invention allows using for storing inside a pharmaceutical packaging a solid pharmaceutical formulation, which may contain a prostacyclin analog as defined below, a reduced amount of a desiccant or a drying agent, which is less than an amount of the desiccant or the drying agent necessary to maintain a relative humidity below 40 % during the whole storing time of a pharmaceutical product. Reducing the amount of a desiccant or a drying agent may lower a cost of the pharmaceutical product.
• the reduced amount of the desiccant drying agent may be no more than 0.9 X grams or no more than 0.85 X grams or no more than 0.8 X grams or no more than 0.75 X grams or no more than 0.7 X grams or no more than 0.65 X grams or no more than 0.6 X grams or no more than 0.55 X grams or no more than 0.5 X grams or no more than 0.45 X grams or no more than 0.4 X grams or no more than 0.35 X grams or no more than 0.3 X or no more than 0.25 X or no more than 0.2 X.
• the reduced amount of the desiccant or the drying agent that the solid formulation at the end of the storage time has a moderate moisture level as defined above.
• the actual reduced amount of a desiccant or drying agent may depend on a number of factors, such as a volume of the unit packaging; a type of the packaging, a seal applied to the packaging, such as a cap; a type of desiccant; a storage time; storage conditions, such as temperature and a relative outside humidity; an amount of the pharmaceutical formulation in the unit packaging.
• the storage time for the product may be 1 month, 2 months, 3 months, 6 months, 9 months, 12 months, 18 months, 24 months, 30 months or 36 months or 42 months or 48 months.
• the storage conditions may include a storage temperature ranging from 10 0 C to 55 0 C, 15 0 C to 50 0 C or from 15 0 C to 45 0 C or any temperature within these ranges and a relative outside humidity (humidity outside the packaging) ranging from 20 % to 100 % or from 30 % to 90 % or from 40 % to 85 % or any integer within these ranges.
• Exemplary storage conditions may be 25 C/ 60% relative humidity (RH), 30 C/75% RH, and 40 C/75% RH.
• the packaging may be any pharmaceutical packaging known in the pharmaceutical arts.
• the packaging may be a bottle packaging, such as a glass or a plastic bottle.
• Plastic bottles for pharmaceutical packaging may be bottles made of a polymer material, such as high density polyethylene (HDPE).
• the packaging may be a blister pack.
• the blister pack may include a forming component and a covering or lidding component, which may be sealed or attached to the forming component.
• the forming component of the blister pack may be shaped to hold a solid dose formulation, such as tablet or capsule formulation.
• the forming component may be composed of a metal, such as aluminum, or a blister-packaging plastic or polymer material, such as polyvinyl chloride (PVC), polyvinylidene chloride (PVDC), Polychlorotrifluoroethylene (PCTFE, commercially sold as ACLAR ®), or polypropylene (PP).
• the covering or lidding component may include a support material, such as aluminum, which can have a sealing agent, such as a heat sealing agent, disposed on one side.
• the packaging may be such that it may maintain the moderate moisture level (as defined above) in the formulation during the storage time of the pharmaceutical product, which may be 1 month, 2 months, 3 months, 6 months, 9 months, 12 months, 18 months, 24 months, 30 months or 36 months or 42 months or 48 months under storage conditions, which may include a storage temperature ranging from 10 0 C to 55 0 C, 15 0 C to 50 0 C or from 15 0 C to 45 0 C or any temperature within these ranges and a relative outside humidity (humidity outside the packaging) ranging from 20 % to 100 % or from 30 % to 90 % or from 40 % to 85 % or any integer within these ranges.
• the moderate moisture level as defined above
• a combination of a) the amount of a desiccant or a drying agent and b) the packaging may be such that it may maintain a humidity level inside the packaging such that a pharmaceutical composition has a moderate moisture level (as defined above) during the storage time of the product, which may be 1 month, 2 months, 3 months, 6 months, 9 months, 12 months, 18 months, 24 months, 30 months or 36 months or 42 months or 48 months under storage conditions, which may include a storage temperature ranging from 10 0 C to 55 0 C, 15 0 C to 50 0 C or from 15 0 C to 45 0 C or any temperature within these ranges and a relative outside humidity ranging from 20 % to 100 % or from 30 % to 90 % or from 40 % to 85 % or any integer within these ranges.
• a moderate moisture level as defined above
• a desiccant or a drying agent may be any desiccant or drying agent, which is used in pharmaceutical arts.
• the desiccant may be bentonite, such sodium bentonite or calcium bentonite; molecular sieve, activated carbon, silica gel or any combination thereof.
• the pharmaceutical product may be such that it is does not contain a desiccant or a drying agent. Omitting a desiccant/drying agent may lower a cost of the pharmaceutical product.
• the solid formulation may be a solid dose formulation, such as a tablet or a capsule, which may be directly administered to a patient.
• the solid formulation may be also in an intermediate form, such as a powder, from which a solid dose formulation, such as a tablet or a capsule, may be formed.
• a mass of the individual solid dose formulation such as may be from 10 mg to 1 g or from 20 mg or 500 mg or from 50 mg to 400 mg or any subrange within these ranges.
• a core of the tablet or capsule, without a coating, such as a functional or color coating may have a mass of about 200 mg.
• a mass of the active agent, such as a prostacyclin analog, in the individual solid dose formulation may vary.
• the active agent is treprostinil diethanolamine
• its mass per the individual solid dose formulation such as a tablet or capsule
• Exemplary mass of treprostinil per individual solid dose formulation may be 0.125 mg, 0.25 mg, 0.5 mg, 1 mg and 2.5 mg or if recalculated in a mass of treprostinil diethanolamine, 0.125x1.27 mg,
• the solid formulation may also include one or more pharmaceutically acceptable excipients.
• the core excipients may include maltodextrin, sodium lauryl sulfate, magnesium stearate and/or xylitol.
• An exemplary pharmaceutical product may include 100 tablets containing treprostinil diethanolamine placed inside of a plastic pharmaceutical bottle, which may be a 45cc
• desiccant such as bentonite clay or silica gel.
• the amount of desiccant in such product may be 0.5 mg or less.
• the product may also contain a stopper or holder, which may prevent the tablets from moving within the bottle and/or breaking apart.
• a stopper or holder may be, for example, a coil, such as a rayon coil.
• a solid dose formulation may be prepared by compressing a powder comprising an active agent disclosed below in the section "Active agent”.
• the powder may contain one or more excipients, such as those disclosed above for treprostinil diethanolamine.
• a mass of the powder for forming a solid dose formulation may vary.
• a solid dose formulation may require from 10 mg to 1000 mg of the powder or from 20 mg to 500 mg or from 50 mg to 400 mg or from 100 mg to 300 mg or from 150 mg to 250 mg or any integer within these ranges.
• a mass concentration of the active agent in the powder may also vary.
• the mass concentration of the active agent in the powder may be from 0.02 % to 3 %, or from 0.03% to 2.5 % or from 0.05 % to 2 %.
• An exemplary mass of the powder for forming a solid dose formulation may be 200 mg.
• a mass concentration of the active agent in the powder can be about 0.079%; for a dose of 0.25 mg (0.25x1.27 mg of treprostinil diethanolamine), about 0.159%; for a dose of about 0.5 mg (0.5x1.27 mg of treprostinil diethanolamine), 0.317 %; for a dose of 1 mg (1x1.27 mg of treprostinil diethanolamine), about 0.63%; for a dose of 2.5 mg (2.5x1.27 mg of treprostinil diethanolamine), about 1.59%.
• the solid dose formulations may prepared from the powder using a press. Presses for preparation solid state formulations are common in the pharmaceutical industry. A moisture level in the powder before pressing may be no more or less than 3 %. After pressing the solid dose formulation may placed inside a pharmaceutical packaging, such a as a bottle, for storing. In addition to the solid dose formulation, one may also place inside the pharmaceutical packaging a desiccant or a drying agent.
• the placed amount of the desiccant or the drying agent may be less than an effective amount that is necessary for maintaining a humidity level below 40 % inside the pharmaceutical packaging for a storage time of the formulation, which may be 1 month, 2 months, 3 months, 6 months, 9 months, 12 months, 18 months, 24 months, 30 months or 36 months or 42 months or 48 months.
• the placed amount of the desiccant or the drying agent may be at most 90 % or at most 85 % or at most 80 % or at most 75 % or at most 70 % or at most 65 % or at most 60 % or at most 55 % or at most 50 % or at most 45 % or at most 40 % or at most 35 % or at most 30 % or at most 25 % or at most 20 % of the effective amount that is necessary for maintaining a relative humidity level below 40 % inside the pharmaceutical packaging for the storage time of the formulation.
• the placed amount of the desiccant or the drying agent may be such that at the end of the storage time the formulation has a moderate moisture level as defined above.
• the solid dose formulation may be removed from the packaging and administered to a subject, such as a human being.
• the active agent may be a compound of formula I:
• R 1 is independently selected from the group consisting of H, substituted and unsubstituted benzyl groups and groups wherein OR 1 are substituted or unsubstituted glycolamide esters; R and R may be the same or different and are independently selected from the group consisting of H, phosphate and groups wherein OR 2 and OR 3 form esters of amino acids or proteins, enantiomers of the compound; and pharmaceutically acceptable salts of the compound.
• R 1 is -CH 2 CONR 4 R 5 and R 4 and R 5 may be the same or different and are independently selected from the group consisting of H, OH, substituted and unsubstituted alkyl groups, -(CH 2 ) m CH 3 , -CH 2 OH, and -CH 2 (CH 2 ) n OH, with the proviso that m is O, 1, 2, 3 or 4, and n is O, 1, 2, 3 or 4.
• R 1 can specifically exclude H, substituted and unsubstituted benzyl groups, or groups wherein OR 1 are substituted or unsubstituted glycolamide esters.
• R 1 is a substituted or unsubstituted benzyl groups, such as - CH 2 C 6 H 5 , -CH 2 C 6 H 4 NO 2 , -CH 2 C 6 H 4 OCH 3 , -CH 2 C 6 H 4 Cl, -CH 2 C 6 H 4 (NO 2 ) 2 , or - CH 2 C 6 H 4 F.
• the benzyl group can be ortho, meta, para, ortho/para substituted and combinations thereof.
• Suitable substituents on the aromatic ring include halogens (fluorine, chlorine, bromine, iodine), -NO 2 groups, -OR 16 groups wherein R 16 is H or a C 1 -C 4 alkyl group, and combinations thereof.
• R 4 and R 5 may be the same or different and are independently selected from the group consisting of H, OH, -CH 3 , and - CH 2 CH 2 OH. In these compounds where R 1 is not H, generally one or both of R 2 and R 3 are H.
• R 2 and R 3 are H and R 1 is -CH 2 CONR 4 R 5 , and one or both of R 4 and R 5 are H, -OH, -CH 3 , -CH 2 CH 2 OH.
• R 2 and R 3 can be independently selected from phosphate and groups wherein OR 2 and OR 3 are esters of amino acids, dipeptides, esters of tripeptides and esters of tetrapeptides. In some embodiments, only one of R 2 or R 3 is a phosphate group. In compounds where at least one of R 2 and R 3 is not H, generally R 1 is H.
• R and R are H and thus the compound of structure I is derivatized at only one of R and R 3 .
• R 2 is H and R 3 is defined as above.
• R 1 and R 3 are H and R 2 is a group wherein OR 2 is an ester of an amino acid or a dipeptide.
• R 1 and R 2 are H and R 3 is a group wherein OR 3 is an ester of an amino acid or a dipeptide.
• OR 2 and OR 3 groups form esters of amino acids or peptides, i.e., dipeptides, tripeptides or tetrapeptides, these can be depicted generically as - COCHR 6 NR 7 R 8 wherein R 6 is selected from the group consisting of amino acid side chains, R and R may be the same or different and are independently selected from the group consisting of H, and -COCHR 9 NR 10 R 11 .
• reference to amino acids or peptides refers to the naturally occurring, or L-isomer, of the amino acids or peptides.
• D-isomer amino acid residues can take the place of some or all of L-amino acids.
• mixtures of D- and L-isomers can also be used.
• R 7 together with R 6 forms a pyrrolidine ring structure.
• R 6 can be any of the naturally occurring amino acid side chains, for example -CH 3 (alanine), -(CH 2 ) 3 NHCNH 2 NH (arginine), -CH 2 CONH 2 (asparagine), ⁇ CH 2 COOH (aspartic acid,), -CH 2 SH (cysteine), -(CH 2 ) 2 CONH 2 (glutamine), - (CH 2 ) 2 COOH (glutamic acid), -H (glycine), -CHCH 3 CH 2 CH 3 (isoleucine), - CH 2 CH(CH 3 ) 2 (leucine), -(CH 2 ) 4 NH 2 (lysine), -(CH 2 ) 2 SCH 3 (methionine), -CH2Ph (phenylalanine), -CH 2 OH (serine), -CHOHCH 3 (threonine), -CH(CH 3 ) 2 (valine),
• Ph designates a phenyl group.
• R 7 and R 8 may be the same or different and are selected from the group consisting of H, and -COCHR 9 NR 10 R 11 , wherein R 9 is a side chain of amino acid, R 10 and R 11 may be the same or different and are selected from the group consisting of H, and -COCHR 12 NR 13 R 14 , wherein R 12 is an amino acid side chain, R 13 and R 14 may be the same or different and are independently selected from the group consisting of H, and -COCHR 15 NH 2 .
• R 9 is a side chain of amino acid
• R 10 and R 11 may be the same or different and are selected from the group consisting of H, and -COCHR 12 NR 13 R 14
• R 12 is an amino acid side chain
• R 13 and R 14 may be the same or different and are independently selected from the group consisting of H, and -COCHR 15 NH 2 .
• the peptide chains can be extended on the following scheme to the desired length and include the desired amino acid residues.
• the peptides can be either homopeptides, i.e., repeats of the same amino acid, such as arginyl-arginine, or heteropeptides, i.e., made up of different combinations of amino acids.
• heterodipeptides include alanyl-glutamine, glycyl-glutamine, lysyl-arginine, etc.
• R 1 is H and one of R 2 or R 3 is a phosphate group or H while the other R 2 or R 3 is a group such the OR 2 or OR 3 is an ester of an amino acid, such as an ester of glycine or alanine.
• the active agent may be (+) treprostinil, which has the following structure:
• Treprostinil is a chemically stable analog of prostacyclin, and as such is a potent vasodilator and inhibitor of platelet aggregation.
• the sodium salt of treprostinil, (lR,2R,3aS,9aS)-[[2,3,3a,4,9,9a -Hexahydro-2-hydroxy -l-[(3S)-3-hydroxyoctyl]-lH- benz[f]inden-5-yl] oxy] acetic acid monosodium salt is sold as a solution for injection as Remodulin® which has been approved by the Food and Drug Administration (FDA) for treatment of pulmonary hypertension.
• FDA Food and Drug Administration
• U.S. Patent no. 5,153,222 discloses use of treprostinil for treatment of pulmonary hypertension.
• U.S. patent no. 5,234,953 discloses treatment of congestive heart failure with treprostinil.
• U.S. patents nos. 6,765,117 and 6,809,223 disclose stereoselective process for treprostinil synthesis.
• U.S. patents nos. 6,521,212 and 6,756,033 describe administration of treprostinil by inhalation for treatment of pulmonary hypertension, peripheral vascular disease and other diseases and conditions.
• U.S. patent no. 6,054,486 discloses treatment of peripheral vascular disease with treprostinil.
• 6,803,386 discloses administration of treprostinil for treating cancer such as lung, liver, brain, pancreatic, kidney, prostate, breast, colon and head-neck cancer.
• U.S. patent application publication no. 2005/0165111 discloses treprostinil treatment of ischemic lesions.
• U.S. patent no. 7,199,157 discloses that treprostinil treatment improves kidney functions.
• U.S. patent application publication no. 2005/0282903 discloses treprostinil treatment of diabetic neuropathic foot ulcers.
• U.S. patent application publication no. 2008/0280986 discloses treatment of interstitial lung disease with reprostinil.
• U.S. patent application publication no. 2008/0200449 discloses administration of Treprostinil via a metered dose inhaler.
• US patent application publication no. 2009/0163738 discloses an alternative process for preparation treprostinil.
• the active agent can be (-)-treprostinil, the enantiomer of (+)- treprostinil.
• the active agent may be a pharmaceutically acceptable salt of Treprostinil.
• the active agent can be the diethanolamine salt of treprostinil.
• the diethanolamine salt of treprostinil can be in an amorphous or a crystalline state. In the crystalline state, the diethanolamine salt of treprostinil can have two polymorphs, with two forms, A and B, which are disclosed in U.S. patents nos. 7,384,978, 7,417,070 and 7,544,713. Of the two forms, B is preferred.
• a particularly preferred embodiment of the present invention may be form B of treprostinil diethanolamine.
• Prostacyclin analogs such as compounds of formula I, may be used in promoting vasodilation, inhibiting platelet aggregation and thrombus formation, stimulating thrombolysis, inhibiting cell proliferation (including vascular remodeling), providing cytoprotection, preventing atherogenesis and inducing angiogenesis.
• the compounds of formula I may be used in the treatment of/for: pulmonary hypertension, ischemic diseases (e.g., peripheral vascular disease, Raynaud's phenomenon, Scleroderma, myocardial ischemia, ischemic stroke, renal insufficiency), heart failure (including congestive heart failure), conditions requiring anticoagulation (e.g., post MI, post cardiac surgery), thrombotic microangiopathy, extracorporeal circulation, central retinal vein occlusion, atherosclerosis, inflammatory diseases (e.g., COPD, psoriasis), hypertension (e.g., preeclampsia), reproduction and parturition, cancer or other conditions of unregulated cell growth, cell/tissue preservation and other emerging therapeutic areas where prostacyclin treatment appears to have a beneficial role.
• ischemic diseases e.g., peripheral vascular disease, Raynaud's phenomenon, Scleroderma, myocardial ischemia, ischemic stroke, renal insufficiency
• the identified impurities in Table 1 are as follows: RRT 0.29 - benzyl hydroxy treprostinil, RRT 0.37 - currently unknown, RRT 0.48 - xylitol ester of treprostinil, RRT 0.55 - xylitol ester of treprostinil, UT- 15 BHEA - is the amide of treprostinil with the counterion, RRT 0.70 - -xylitol ester of treprostinil, RRT 0.72 - xylitol ester of treprostinil, 3AU90 is an isomer of treprostinil, UT- 15 CPK is the cyclopentyl ketone of treprostinil, UT- 15 SCK is the side chain ketone of treprostinil, 750W93 is an ester dimer of treprostinil, and 751W93 is a 3-
• the tablets were stored in either bottles with or without desiccant or blistered packages in an environment with a temperature of 40 0 C and 75 % relative humidity (40C/75% RH).
• the bottles with desiccant have the least amount of moisture exposure to the tablets, followed by bottles without desiccant, and the highest moisture environment for the tablets is the blisters.
• the moisture levels of the tablets at one and three months were measured for each packaging condition. As the moisture level increases, especially above 3%, that the impurity levels decrease for each as well as the total, see Table 2. This result is surprising and counterintuitive because typically for solid-dosage forms minimization of moisture levels is recommended. Table 2.
• Table 3 provides the stability data for 1-mg lots that were placed on stability with a 1- gram desiccant at 40 CIl 5% RH. Table 3 also provides the moisture levels.
• Table 4 provides the stability data for 1-mg lots that were placed on stability without a desiccant at 40 C/75% RH. I have also provided the moisture levels at each time point. You can see the moisture level slowly rises over time without desiccant and to a much lesser extent with desiccant. The impurity profile looks better without desiccant. You can remove the columns for the methods and clinical lot numbers. Table 3

Landscapes

• Health & Medical Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Epidemiology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Cardiology (AREA)
• General Chemical & Material Sciences (AREA)
• Emergency Medicine (AREA)
• Heart & Thoracic Surgery (AREA)
• Hospice & Palliative Care (AREA)
• Urology & Nephrology (AREA)
• Vascular Medicine (AREA)
• Dermatology (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Medicinal Preparation (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Priority Applications (4)

Applications Claiming Priority (2)

Publications (1)

Family

ID=43050464

Family Applications (1)

Country Status (7)

Cited By (9)

Families Citing this family (25)

Citations (3)

Family Cites Families (21)

• 2010
  • 2010-05-06 JP JP2012509968A patent/JP5649645B2/ja active Active
  • 2010-05-06 CA CA2760499A patent/CA2760499C/en active Active
  • 2010-05-06 WO PCT/US2010/033852 patent/WO2010129757A1/en not_active Ceased
  • 2010-05-06 KR KR1020117028834A patent/KR101544246B1/ko active Active
  • 2010-05-06 EP EP10772819.8A patent/EP2427054A4/en not_active Withdrawn
  • 2010-05-06 CN CN201080019951.3A patent/CN102421288B/zh active Active
  • 2010-05-06 US US12/775,102 patent/US8349892B2/en active Active

Patent Citations (5)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events